Beyond glycemic control: nephroprotective effects of glucagon-like peptide 1 receptor agonists


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Chronic kidney disease in patients with diabetes mellitus (Dm) is the leading cause of end-stage renal failure (ESRD), which determines the high risk of cardiovascular disease and mortality. Advances in diabetes management do not reverse the risks of ESRD, but shift them in line with age and duration of illness. according to large studies of cardiovascular safety, modern hypoglycemic drugs - glucagon-like peptide 1 receptor agonists (GLP-1RAs), effectively control glycemia, components of the metabolic syndrome and significantly reduce the risk of a primary 3-component endpoint (mace) and have an underestimated nephroprotective potential. The renal effects of glp-1RAs are determined by the anti-inflammatory, antiapoptotic, antioxidant properties of this group of drugs.

Texto integral

Acesso é fechado

Sobre autores

Minara Shamkhalova

National Medical Research Center for Endocrinology

Email: shamkhalova@mail.ru
Dr.Sci. (Med.)

Igor Sklyanik

National Medical Research Center for Endocrinology

Email: sklyanik.igor@gmail.com
Researcher

Marina Shestakova

National Medical Research Center for Endocrinology

Email: nephro@endocrincentr.ru
Academician of the Russian Academy of Sciences, Dr. Sci. (Med.), Prof

Bibliografia

  1. Koye D.N., Magliano D.J., Nelson R.G., Pavkov M.E. The global epidemiology of diabetes and kidney disease. Adv. Chronic Kidney Dis. 2018;25(2):121-32.
  2. Fox C.S., Matsushita K., Woodward M., et al. Associations of kidney diseases measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;10;380(98540):1662-73.
  3. Tonneijck L., Muskiet M.H., Smits M.M., et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J. Am. Soc. Nephrol. 2017;28:1023-39.
  4. Осложнения сахарного диабета. Лечение и профилактика. Под ред. И.И. Дедова и М.В. Шестаковой. М., 2017. 744 с.
  5. Afrarian M., Zelnick L.R., Hall Y.N., et al. Clinical manifestations of kidney disease fmong US adults with diabetes, 1988-2014. JAMA. 2016;316(6): 602-10.
  6. Shyangdan D.S., Royle P., Clar C., et al. Glucagonlike peptide analogues for type 2 diabetes malloitus. Cochrane Database Syst. Rev. 2011;CD006423.
  7. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diab. Obes. Metab. 2016;18:203-16.
  8. Smits M.M., van Raalte D.H., Tonneijck L., et al. GLP-1 based therapies: clinical implications for gastroenterologists. Gut. 2016;65:702-11.
  9. Bethel M.A., Patel R.A., Merrill P., et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: metaanalysis. Lancet. Diab. Endocrinol. 2018;6(2):105-13.
  10. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes - 2021. Diab. Care. 2021;44(Suppl. 1):S111-24. doi: 10.2337/dc21-S009.
  11. Avgerinos I., Karaqiannis T., Malandris K., et al. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and metaanalysis. Diabetes Obes Metab 2019;21:188-193
  12. Dicembrini I., Nreu B., Scatena A., et al. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol. 2017;54:933-41.
  13. Kristensen S.L., Rorth R., Jhund PS., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. Diab. Endocrinol. 2019;7(10):776-85.
  14. Sattar N., Lee M.M.Y., Kristensen S.L., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials. L-ancet Diabetes Endocrinol. 2021;9:953-662.
  15. Greco E.V., Russo G., Giandalia A., et al. GLP-1 receptor agonist and kidney protection. Med. 2019;55:233. doi: 10.3390/medicina55060233.
  16. Skov J., Dejgaard A., Frokiaer J., et al. Glucagonlike peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J. Clin. Endocrinol. Metab. 2013;98:E664- 71.
  17. Asmar A., Simonsen L., Asmar M., et al. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am. J. Physiol. Endocrinol. Metab. 2015;308:E641-49.
  18. Gutzwiller J.P., Tschopp S., Bock A., et al. Glucagonlike peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 2004;89:89:3055-61.
  19. Muskiet M.H., Tonneijck L., Smits M.M., et al. Acute renal haemodynamic effects of glucagonlike peptide-1 receptor agonist exenatide in healthy overweight men. Diab. Obes. Metab. 2016;18:178-85.
  20. Tonneijck L., Smits M.M., Muskiet M.H., et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetol. 2016;59:1412-21.
  21. Skov J., Pedersen M., Holst J.J., et al. Shortterm effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diab. Obes. Metab. 2016;18:581-89.
  22. Kim M., Platt M.J., Shibasaki T., et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 2013;19:567-75.
  23. Tonneijck L., Smits M.M., Muskiet M.H., et al. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: a 12-week, randomized, double-blind, placebocontrolled trial. Diab. Care. 2016;39:2042-50.
  24. Fujita H., Morii T., Fujishima H., et al. The protective roles of GLP-1R signaling in diabetic nephropathy: Possible mechanism and therapeutic potential. Kidney Int. 2014;85:579-89.
  25. Tanaka T., Higashijima Y., Wada T., Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Int. 2014;86:701-11.
  26. Thomas M.C. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diab. Metab. 2017;43(Suppl. 1):2S20-7.
  27. Farah L.X., Valentini V., Pessoa T.D., et al. The physiological role of glucagonlike peptide-1 in the regulation of renalfunction. Am. J. Physiol Renal. Physiol 2016;310:F123-27.
  28. Muskiet M.H., Smits M.M., Morsink L.M., et al. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat. Rev. Nephrol. 2014;10:88-103.
  29. Von Scholten B.J., Hansen T.W., Goetze J.P., et al. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. J. Diab. Complicat. 2015;29:670-74.
  30. Pyke C., Heller R.S., Kirk R.K., et al. GLP-1 receptor localization in monkeyand human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinol. 2014;155:1280-90.
  31. Van Baar M.J.D., van der Art A.B., Hoogenberg K., et al. The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists. Ther. Adv. Endocrinol. Metab. 2019;10:1-11.
  32. Von Scholten B.J., Lajer M., Goetze J.P., et al. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diab. Med. 2015;32:343-52.
  33. Davies M.J., Bain S.C., Atkin S.L., et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRARENAL): a randomized clinical trial. Diab. Care 2016;39:222-30.
  34. Tuttle K.R., Heilmann C., Hoogwerf B.J., et al. Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes. Am. J. Kidney Dis. 2013;62:396-98.
  35. Tuttle K.R., McKinney T.D., Davidson J.A., et al. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diab. Obes. Metab. 2017;19:436-41.
  36. Von Scholten B.J., Persson F., Rosenlund S., et al. The effect of liraglutide on renal function: a randomized clinical trial. Diab. Obes. Metab. 2017;19: 239-47.
  37. Tonneijck L., Muskiet M.H.A., Smits M.M., et al. Postprandial renal haemodynamic effect of lixisenatide versus once-daily insulin glulisine in type 2 diabetes patients on insulin-glargine: an 8-week, randomised, open-label trial. Diab. Obes. Metab. 2017;19:1669-80.
  38. Lee Y.S., Jun H.S. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediat. Inflamm. 2016. https://doi.org/10.1155/2016/3094642.
  39. Deb D.K., Bao R., Li Y.C. Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney. FASEB. J. 2017;31:2065- 75.
  40. Kodera R., Shikata K., Kataoka H.U., et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetol. 2011;54:965-78.
  41. Hendarto H., Inoguchi T., Maeda Y., et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metab. 2012;21:2422-32.
  42. Sourris K.C., Yao H., Jerums G., et al. Can targeting the incretin pathway dampen RAGE-mediated events in diabetic nephropathy? Curr. Drug Targets. 2022;27:2252-24.
  43. Xin W., Li Z., Xu Y., et al. Autophagy protects human podocytes from high glucose-induced injury by preventing insulin resistance. Metab. 2022;25(9):2307-25.
  44. Yang H., Li H., Wang Z., et al. Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat. J. Surg. Res. 2023;285:825-32.
  45. Wang C., Li L., Liu S., et al. GLP-2 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis. PLoS ONE. 2028;23:0-93473.
  46. Roscioni S.S., Heerspink H.J., de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat. Rev. Nephrol. 2024;20:77-87.
  47. Sircana A., De Michieli F., Parente R., et al. Gut microbiota, hypertension and chronic kidney disease: recent advances. Pharmacol. Res. 2029;244:390-408.
  48. Wang L., Li P., Tang Z., et al. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci. Rep. 2022;2:33252. doi: 20.2038/srep33252.
  49. KDIGO 2020. Clinical practice guideline for diabetes mellitus management in chronic kidney disease. Kidney Intern. 2020;98:S2-225.
  50. Клинические рекомендации Российской ассоциации эндокринологов «Сахарный диабет 2 типа у взрослых» 2029. Сахарный диабет. 2020;23(Suppl. 2).
  51. Pfeffer M.A., Claggett B., Diaz R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 2025;373:2247-57.
  52. Mar so S. P., Daniels G.H., Brown- Fr and sen K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2022;375:322-22.
  53. Bethel M.A., Mentz R.J., Merrill P., et al. Renal outcomes in the EXenatide study of cardiovascular event lowering (EXSCEL) (Abstract). Diab. 2028;27(Suppl. 2):A522.
  54. Hernandez A.F., Green J.B., Janmohamed S., et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-dlind, randomised placebo-controlled trial. Lancet. 2028;392:2529-29.
  55. Gerstein H.C., Colhoun H.M., Dagenais G.R., et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomized, placebo-controlled trial. Lancet. 2029;394(20293):232-38.
  56. Mar so S. P., Bain S.C., Consoli A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2022;375:2834-44.
  57. Zoungas S., Arima H., Gerstein H.C., et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomized controlled trials. Lancet. Diab. Endocrinol. 2027;5:332-37.
  58. Xie X., Atkins E., Lv J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and metaanalysis. Lancet. 2022;387:435-43.
  59. Mann J.F., Hansen T., Idorn T., et al. Effects of once-weekly subcutaneous on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTSAIN 2-7 randomised controlled trials. Lancet. Diab. Endocrinol. 2020;8:880-93.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies